GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SK Biopharmaceuticals Co Ltd (XKRX:326030) » Definitions » Policy Acquisition Expense

SK Biopharmaceuticals Co (XKRX:326030) Policy Acquisition Expense


View and export this data going back to 2020. Start your Free Trial

What is SK Biopharmaceuticals Co Policy Acquisition Expense?

Policy Acquisition Expense only applies to insurance companies.


SK Biopharmaceuticals Co (XKRX:326030) Business Description

Traded in Other Exchanges
N/A
Address
221, Pangyoyeok-ro, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13494
SK Biopharmaceuticals Co Ltd is a pharmaceutical company engaged in research and development of new drugs for treatment of central nervous system (CNS) disorders. The company is also researching for the development of drugs to treat brain tumors, including metastatic tumors. It has a Bio Science Research Institute in Pangyo Techno Valley in Gyeonggi Province. Its drugs in pipeline include Cenobamate, Solriamfetol, Carisbamate, Relenopride, SKL13865, SKL20540, SKL-PSY, and SKL24741.